International consensus on use of continuous glucose monitoring
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
International consensus on use of continuous glucose monitoring. / Danne, Thomas; Nimri, Revital; Battelino, Tadej; Bergenstal, Richard M.; Close, Kelly L.; DeVries, J. Hans; Garg, Satish; Heinemann, Lutz; Hirsch, Irl; Amiel, Stephanie A.; Beck, Roy; Bosi, Emanuele; Buckingham, Bruce; Cobelli, Claudio; Dassau, Eyal; Doyle, Francis J.; Heller, Simon; Hovorka, Roman; Jia, Weiping; Jones, Tim; Kordonouri, Olga; Kovatchev, Boris; Kowalski, Aaron; Laffel, Lori; Maahs, David; Murphy, Helen R.; Nørgaard, Kirsten; Parkin, Christopher G.; Renard, Eric; Saboo, Banshi; Scharf, Mauro; Tamborlane, William V.; Weinzimer, Stuart A.; Phillip, Moshe.
In: Diabetes Care, Vol. 40, No. 12, 2017, p. 1631-1640.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - International consensus on use of continuous glucose monitoring
AU - Danne, Thomas
AU - Nimri, Revital
AU - Battelino, Tadej
AU - Bergenstal, Richard M.
AU - Close, Kelly L.
AU - DeVries, J. Hans
AU - Garg, Satish
AU - Heinemann, Lutz
AU - Hirsch, Irl
AU - Amiel, Stephanie A.
AU - Beck, Roy
AU - Bosi, Emanuele
AU - Buckingham, Bruce
AU - Cobelli, Claudio
AU - Dassau, Eyal
AU - Doyle, Francis J.
AU - Heller, Simon
AU - Hovorka, Roman
AU - Jia, Weiping
AU - Jones, Tim
AU - Kordonouri, Olga
AU - Kovatchev, Boris
AU - Kowalski, Aaron
AU - Laffel, Lori
AU - Maahs, David
AU - Murphy, Helen R.
AU - Nørgaard, Kirsten
AU - Parkin, Christopher G.
AU - Renard, Eric
AU - Saboo, Banshi
AU - Scharf, Mauro
AU - Tamborlane, William V.
AU - Weinzimer, Stuart A.
AU - Phillip, Moshe
PY - 2017
Y1 - 2017
N2 - Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide themeans to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to themost appropriate glucose monitoring methodologies, as well as standardized advice about howbest to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
AB - Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide themeans to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to themost appropriate glucose monitoring methodologies, as well as standardized advice about howbest to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
U2 - 10.2337/dc17-1600
DO - 10.2337/dc17-1600
M3 - Journal article
C2 - 29162583
AN - SCOPUS:85036620716
VL - 40
SP - 1631
EP - 1640
JO - Diabetes Care
JF - Diabetes Care
SN - 0149-5992
IS - 12
ER -
ID: 189362433